Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Expenses (2022 - 2026)

Centessa Pharmaceuticals has reported Operating Expenses over the past 4 years, most recently at $68.5 million for Q4 2025.

  • Quarterly Operating Expenses fell 8.19% to $68.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $222.7 million through Dec 2025, up 10.76% year-over-year, with the annual reading at $222.7 million for FY2025, 10.76% up from the prior year.
  • Operating Expenses was $68.5 million for Q4 2025 at Centessa Pharmaceuticals, up from $53.8 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $74.6 million in Q4 2024 and troughed at $36.1 million in Q1 2024.
  • The 4-year median for Operating Expenses is $47.9 million (2023), against an average of $50.8 million.
  • Year-over-year, Operating Expenses crashed 31.27% in 2023 and then soared 77.44% in 2024.
  • A 4-year view of Operating Expenses shows it stood at $41.6 million in 2022, then rose by 1.03% to $42.0 million in 2023, then soared by 77.44% to $74.6 million in 2024, then dropped by 8.19% to $68.5 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Operating Expenses are $68.5 million (Q4 2025), $53.8 million (Q3 2025), and $54.7 million (Q2 2025).